Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-06-03

Clinical Trial Update: A Phase 2 Study of E6005 in Patients With Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the investigational agent E6005 in patients with Atopic Dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • E6005

Snippet

Sponsor: Organon and Co | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED